Core Insights - Vaxcyte's VAX-31 has shown promising results in a Phase 1/2 study, demonstrating robust immune responses and a safety profile comparable to Prevnar 20® [1][2][3] - The vaccine is designed to cover approximately 95% of invasive pneumococcal disease (IPD) and 88% of pneumococcal pneumonia in U.S. adults aged 50 and older, potentially offering broader coverage than current vaccines [1][8] Study Results - VAX-31 was well tolerated across all doses, with a safety profile similar to PCV20, and no serious adverse events related to the vaccine were reported [2][10] - The High Dose of VAX-31 met or exceeded non-inferiority criteria for all 20 serotypes common with PCV20 and demonstrated superior immune responses for 11 additional serotypes unique to VAX-31 [2][10] Immunogenicity Findings - VAX-31 demonstrated high geometric mean concentrations (GMCs) of immunoglobulin G (IgG) across all 31 serotypes, consistent with opsonophagocytic activity (OPA) results [10] - At the High Dose, 18 of 20 serotypes showed greater immune responses compared to PCV20, with seven achieving statistically significant higher responses [2][10] Future Development - Based on the study results, VAX-31 has advanced into a comprehensive Phase 3 adult program, with topline data expected in Q4 2026 [1][3] - The OPUS Phase 3 trials aim to support a Biologics License Application, contingent on study outcomes [3][10] About Pneumococcal Disease - Pneumococcal disease, caused by Streptococcus pneumoniae, leads to significant morbidity and mortality, particularly in older adults and young children, highlighting the need for broader-spectrum vaccines [7][8] - The CDC identifies drug-resistant strains of Streptococcus pneumoniae as a serious threat, underscoring the urgency for effective vaccination strategies [7]